885675-66-1

Basic information

• Product Name: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE
• Synonyms: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE;Thieno[3,2-d]pyriMidine, 2-chloro-6-[[4-(Methylsulfonyl)-1-piperazinyl]Methyl]-4-(4-Morpholinyl)-;4-(2-Chloro-6-((4-(methylsulfonyl)piperazin-1-yl)-methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine;2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE-8;2-chloro-6-((4-methanesulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine;4-(2-Chloro-6-((4-(methylsulfonyl)piperazin-1-yl)-methyl)thieno[3,2-d]pyrimidin-4-yl)morpholin
• CAS NO: 885675-66-1
• Molecular Formula: C₁₆H₂₂ClN₅O₃S₂
• Molecular Weight: 431.96058
• Mol File: 885675-66-1.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE(885675-66-1)
• EPA Substance Registry System: 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE(885675-66-1)

Safety Data

• Hazardous Substances Data: 885675-66-1(Hazardous Substances Data)

Usage

General Description

2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE is a chemical compound that contains a thiophene ring fused to a pyrimidine ring, with a chloro substitution at the 2-position and a piperazine moiety with a methanesulfonyl group at the 6-position. It also contains a morpholine ring at the 4-position. 2-CHLORO-6-(4-METHANESULFONYL-PIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YL-THIENO[3,2-D]PYRIMIDINE is of interest in medicinal chemistry and drug discovery due to its potential biological activities, such as anticancer or antiviral properties. It may be used as a starting point for the development of novel pharmaceutical agents targeting specific disease pathways.

Upstream product

• 885618-31-5 2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde 
• 161357-89-7 1-(methylsulfonyl)piperazine hydrochloride 
• 55276-43-2 4-methanesulfonylpiperazine 
• 149-73-5 trimethyl orthoformate 
• 16233-51-5 1H-thieno[3,2-d]pyrimidine-2,4-dione 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 16234-14-3 2,4-dichlorothieno[3,2-d]pyrimidine 
• 16234-15-4 2-chloro-4-morpholinothieno[3,2-d]pyrimidine 
• 1381841-06-0 4-(2-chloro-6-(chloromethyl)thieno[3,2-d]pyrimidin-4-yl)morpholine 
• 885698-97-5 2-chloro-4-morpholinylthiophene[3,2-d]pyrimidine-6-methanol 
• 1416327-30-4 1-((4-(methylsulfonyl)piperazin-1-yl)methyl)-1H-benzotriazole 
• 164331-38-8 tert-butyl 4-(methylsulfonyl)piperazine-1-carboxylate 

Downstream Products

• 957054-30-7 pictilisib 
• 956032-81-8 (3-(6-((4-(methanesulfonyl)piperazin-1-yl)methyl)-4-morpholino-thieno[3,2-d]pyrimidin-2-yl)phenyl)methanol 
• 1204033-31-7 4-[6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-phenylamine 
• 1204033-28-2 4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-phenylthieno[3,2-d]pyrimidin-4-yl)morpholine 
• 1381841-08-2 C₂₆H₃₃N₇O₄S₂ 
• 1381841-09-3 C₂₇H₃₅N₇O₄S₂ 
• 1381841-10-6 C₂₇H₃₅N₇O₄S₂ 
• 1381841-11-7 C₂₇H₃₇N₇O₄S₂ 
• 1381841-12-8 C₃₁H₄₅N₇O₄S₂ 
• 1381841-15-1 C₂₃H₂₈ClN₇O₄S₂ 
• 1381841-16-2 C₂₃H₂₇Br₂N₇O₄S₂ 
• 1394047-46-1 (E)-4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-(3,4,5-trimethoxybenzylidene)hydrazinyl)thieno[3,2-d]pyrimidin-4-yl)morpholine 
• 1394047-47-2 (E)-4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-(2,3,4-trimethoxybenzylidene)hydrazinyl)thieno[3,2-d]pyrimidin-4-yl)morpholine 
• 1394047-53-0 (E)-4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-(4-(trifluoromethoxy)benzylidene)hydrazinyl)thieno[3,2-d]-pyrimidin-4-yl)morpholine 

Relevant articles and documents

Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies

Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed

Phosphoinositides 3-serinekinase inhibitor compd. antialopecic agent and combinations, and method of use

Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

A practical synthesis of a PI3K inhibitor under noncryogenic conditions via functionalization of a lithium triarylmagnesiate intermediate

We report a practical synthesis of PI3K inhibitor GDC-0941. The synthesis was achieved using a convergent approach starting from a thienopyrimidine intermediate through a sequence of formylation and reductive amination followed by Suzuki-Miyaura cross-coupling. Metalation of the thienopyrimidine intermediate involving the intermediacy of triarylmagnesiates allowed formylation under noncryogenic conditions to produce the corresponding aldehyde. We also investigated aminoalkylation via a benzotriazolyl-piperazine substrate as an alternative to the reductive amination route. We evaluated both palladium and nickel catalyzed processes for the borylation and Suzuki-Miyaura cross-coupling. Final deprotection and salt formation afforded the API.